Cargando…
Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study
BACKGROUND: We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections. METHODS: Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156011/ https://www.ncbi.nlm.nih.gov/pubmed/30213012 http://dx.doi.org/10.1097/MD.0000000000012398 |
_version_ | 1783358012616867840 |
---|---|
author | Shi, Hui-Juan Song, Hongbin Zhao, Qian-Ying Tao, Chun-Xia Liu, Min Zhu, Qin-Qin |
author_facet | Shi, Hui-Juan Song, Hongbin Zhao, Qian-Ying Tao, Chun-Xia Liu, Min Zhu, Qin-Qin |
author_sort | Shi, Hui-Juan |
collection | PubMed |
description | BACKGROUND: We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections. METHODS: Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated. RESULTS: Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group. CONCLUSIONS: This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections. |
format | Online Article Text |
id | pubmed-6156011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-61560112018-11-08 Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study Shi, Hui-Juan Song, Hongbin Zhao, Qian-Ying Tao, Chun-Xia Liu, Min Zhu, Qin-Qin Medicine (Baltimore) Research Article BACKGROUND: We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections. METHODS: Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated. RESULTS: Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group. CONCLUSIONS: This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections. Wolters Kluwer Health 2018-09-14 /pmc/articles/PMC6156011/ /pubmed/30213012 http://dx.doi.org/10.1097/MD.0000000000012398 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Shi, Hui-Juan Song, Hongbin Zhao, Qian-Ying Tao, Chun-Xia Liu, Min Zhu, Qin-Qin Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study |
title | Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study |
title_full | Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study |
title_fullStr | Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study |
title_full_unstemmed | Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study |
title_short | Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study |
title_sort | efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: a prospective and randomized clinical study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156011/ https://www.ncbi.nlm.nih.gov/pubmed/30213012 http://dx.doi.org/10.1097/MD.0000000000012398 |
work_keys_str_mv | AT shihuijuan efficacyandsafetyofcombinedhighdoseinterferonandredlighttherapyforthetreatmentofhumanpapillomavirusandassociatedvaginitisandcervicitisaprospectiveandrandomizedclinicalstudy AT songhongbin efficacyandsafetyofcombinedhighdoseinterferonandredlighttherapyforthetreatmentofhumanpapillomavirusandassociatedvaginitisandcervicitisaprospectiveandrandomizedclinicalstudy AT zhaoqianying efficacyandsafetyofcombinedhighdoseinterferonandredlighttherapyforthetreatmentofhumanpapillomavirusandassociatedvaginitisandcervicitisaprospectiveandrandomizedclinicalstudy AT taochunxia efficacyandsafetyofcombinedhighdoseinterferonandredlighttherapyforthetreatmentofhumanpapillomavirusandassociatedvaginitisandcervicitisaprospectiveandrandomizedclinicalstudy AT liumin efficacyandsafetyofcombinedhighdoseinterferonandredlighttherapyforthetreatmentofhumanpapillomavirusandassociatedvaginitisandcervicitisaprospectiveandrandomizedclinicalstudy AT zhuqinqin efficacyandsafetyofcombinedhighdoseinterferonandredlighttherapyforthetreatmentofhumanpapillomavirusandassociatedvaginitisandcervicitisaprospectiveandrandomizedclinicalstudy |